التهاب المفاصل الالتهابي المزمن بكريستالات CPP: ماذا نفعل عندما لا يكون الميثوتريكسات قد نجح

References

DOI: 10.3389/fmed.2024.1327715

• A subset of patients with CPP arthritis may present with symptoms of chronic joint inflammation that can be mistaken for RA.
• Chronic CPP crystal arthritis, on the other hand, is a chronic inflammatory oligoarthritis or polyarthritis.
• The use of tocilizumab, a monoclonal antibody targeting the IL-6 receptor, has been tested in treating persistent CPP arthritis.
• An open-label pilot study involving 11 CPPD patients with either prior treatment failure, contraindication, or intolerance to other medications, showed promising results with tocilizumab.
• Cipolletta et al. reported that in chronic CPP arthritis, the response rate to anakinra was 42.9%.
• Nevertheless, all the studies included in the analysis showed that anakinra could prevent the onset of new flares in chronic CPP arthritis.
• After 3 months, the median global assessment VAS significantly reduced from 60 to 15 (p = 0.006), and treatment efficacy was sustained during a median 10-month follow-up.